Kala Pharmaceuticals (NASDAQ:KALA) was downgraded by investment analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued on Saturday.

Other analysts have also issued research reports about the stock. HC Wainwright set a $37.00 price target on shares of Kala Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, September 10th. Wells Fargo & Co reiterated a “buy” rating on shares of Kala Pharmaceuticals in a research report on Thursday, August 23rd. Zacks Investment Research upgraded shares of Kala Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a research report on Wednesday, July 18th. Finally, Wedbush set a $47.00 price target on shares of Kala Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, August 9th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. Kala Pharmaceuticals currently has an average rating of “Buy” and an average price target of $28.45.

NASDAQ KALA opened at $7.93 on Friday. The company has a current ratio of 9.79, a quick ratio of 9.79 and a debt-to-equity ratio of 0.27. The company has a market cap of $263.53 million, a P/E ratio of -1.36 and a beta of -1.12. Kala Pharmaceuticals has a 1 year low of $7.60 and a 1 year high of $22.10.

Kala Pharmaceuticals (NASDAQ:KALA) last posted its quarterly earnings results on Thursday, August 9th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.10). Equities analysts expect that Kala Pharmaceuticals will post -2.25 EPS for the current year.

In related news, Director Gregory Grunberg bought 606,060 shares of the business’s stock in a transaction on Friday, October 5th. The shares were purchased at an average price of $8.25 per share, for a total transaction of $4,999,995.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Ra Capital Healthcare Fund Lp bought 2,424,242 shares of the business’s stock in a transaction on Wednesday, October 3rd. The stock was bought at an average price of $8.25 per share, for a total transaction of $19,999,996.50. The disclosure for this purchase can be found here. Company insiders own 35.58% of the company’s stock.

Institutional investors have recently modified their holdings of the business. Alps Advisors Inc. acquired a new stake in Kala Pharmaceuticals in the second quarter valued at approximately $489,000. Northern Trust Corp boosted its position in Kala Pharmaceuticals by 82.2% in the first quarter. Northern Trust Corp now owns 133,004 shares of the company’s stock valued at $2,106,000 after buying an additional 60,000 shares in the last quarter. Paloma Partners Management Co acquired a new stake in Kala Pharmaceuticals in the second quarter valued at approximately $152,000. Brown Advisory Inc. acquired a new position in shares of Kala Pharmaceuticals during the first quarter worth $3,957,000. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Kala Pharmaceuticals by 489.8% during the first quarter. The Manufacturers Life Insurance Company now owns 11,778 shares of the company’s stock worth $186,000 after purchasing an additional 9,781 shares during the period. Hedge funds and other institutional investors own 53.61% of the company’s stock.

About Kala Pharmaceuticals

Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. Its product candidates include KPI-121 1.0%, which has completed Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; INVELTYS that has completed Phase III clinical trials for the temporary relief of the signs and symptoms of dry eye disease; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.

Featured Article: Stock Selection – What is cash flow?

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.